The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000
Open accessAbstract
Posaconazole, ravuconazole, and voriconazole are new triazole derivatives that possess potent, broad-spectrum antifungal activity. We evaluated the in vitro activity of these investigational triazoles compared with that of itraconazole and amphotericin B against 239 clinical isolates of filamentous fungi from the SENTRY Program, including Aspergillus spp. (198 isolates), Fusarium spp. (7 isolates), Penicillium spp. (19 isolates), Rhizopus spp. (4 isolates), Mucor spp. (2 isolates), and miscellaneous species (9 isolates). The isolates were obtained from 16 different medical centers in the United States and Canada between January and December 2000. In vitro susceptibility testing was performed using the microdilution broth method outlined in the National Committee for Clinical Laboratory Standards M38-P document. Overall, posaconazole was the most active compound, inhibiting 94% of isolates at a MIC of ≤1 μg/ml, followed by voriconazole (91%), amphotericin B (89%), ravuconazole (88%), and itraconazole (70%). All three new triazoles demonstrated excellent activity (MIC, ≤1 μg/ml) against Aspergillus spp. (114 Aspergillus fumigatus , 22 Aspergillus niger , 13 Aspergillus flavus , 9 Aspergillus versicolor , 8 Aspergillus terreus , and 32 Aspergillus spp.): posaconazole (98%), voriconazole (98%), ravuconazole (92%), amphotericin B (89%), and itraconazole (72%). None of the triazoles were active against Fusarium spp. (MIC at which 50% of the isolates tested were inhibited [MIC 50 ], >8 μg/ml) or Mucor spp. (MIC 50 , >8 μg/ml). Posaconazole and ravuconazole were more active than voriconazole against Rhizopus spp. (MIC 50 , 1 to 2 μg/ml versus >8 μg/ml, respectively). Based on these results, all three new triazoles exhibited promising activity against Aspergillus spp. and other less commonly encountered isolates of filamentous fungi. The clinical value of these in vitro data remains to be seen, and in vitro-in vivo correlation is needed for both new and established antifungal agents. Surveillance efforts should be expanded in order to monitor the spectrum of filamentous fungal pathogens and their in vitro susceptibility as these new antifungal agents are introduced into clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Aspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Trends in the postmortem epidemiology of invasive fungal infections at a University Hospital
Groll, A. H., Shah, P. M., Mentzel, C., Schneider, M., Just-Nuebling, G., & Huebner, K. (1996) · Journal of Infection · doi:10.1016/s0163-4453(96)92700-0 · Cited by 778
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521
Self-citationKao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Self-citationRees, J. R., Pinner, R. W., Hajjeh, R. A., Brandt, M. E., & Reingold, A. L. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1138 · Cited by 397 · cited 3×
“4 cases per million people per year in the United States (35).”
BackgroundPfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Self-citationWingard, J. R., Kubilis, P., Lee, L., Yee, G., White, M., Louise, W., Bowden, R., Anaissie, E., Hiemenz, J., & Lister, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313498 · Cited by 368
Uncommon opportunistic fungi: new nosocomial threats
Groll, A. H., & Walsh, T. J. (2001) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2001.tb00005.x · Cited by 305
Espinel-Ingroff, A. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.954-958.2001 · Cited by 296
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Hollis, R. J., Messer, S. A., & Group, F. T. S. P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.1886-1889.1998 · Cited by 281
Self-citationPfaller, M. A., Jones, R. N., Doern, G. V., Fluit, A. C., Verhoef, J., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., & Hollis, R. J. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00046-2 · Cited by 264
Self-citationIntroduction to Antifungal Drugs
Dismukes, W. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313748 · Cited by 262
Denning, D. W., Marinus, A., Cohen, J., Spence, D., Herbrecht, R., Pagano, L., Kibbler, C., Kermery, V., Offner, F., Cordonnier, C., et al. (1998) · Journal of Infection · doi:10.1016/s0163-4453(98)80173-4 · Cited by 256
The New Fungal Opportunists Are Coming
Perfect, J. R., & Schell, W. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s112 · Cited by 224
Radford, S. A., Johnson, E. M., & Warnock, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.841 · Cited by 189
Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.857-869.2001 · Cited by 179
Burden of aspergillosis-related hospitalizations in the United States
Dasbach, E. J., Davies, G. M., & Teutsch, S. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317487 · Cited by 159
The VISA/GISA problem: therapeutic implications
Liñares, J. (2001) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2001.00054.x · Cited by 153
Murphy, M., Bernard, E. M., Ishimaru, T., & Armstrong, D. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.696 · Cited by 151
Walsh, T. J., Hiemenz, J. W., & Anaissie, E. J. (1996) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70303-2 · Cited by 136
In vitro evaluation of voriconazole against some clinically important fungi
McGinnis, M. R., Pasarell, L., Sutton, D. A., Fothergill, A. W., Cooper, C. R., & Rinaldi, M. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1832 · Cited by 130
Caillot, D., Mannone, L., Cuisenier, B., & Couaillier, J. F. (2001) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2001.tb00010.x · Cited by 127
Brandt, M. E., Pfaller, M. A., Hajjeh, R. A., Hamill, R. J., Pappas, P. G., Reingold, A. L., Rimland, D., & Warnock, D. W. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3065-3069.2001 · Cited by 125
Self-citationCacciapuoti, A. F., Loebenberg, D., Corcoran, E., Menzel, F., Moss, E. L., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C. A., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2017-2022.2000 · Cited by 115
Martin, M. V., Yates, J. O., & Hitchcock, C. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.13 · Cited by 110
Oakley, K. L., Morrissey, G., & Denning, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1504 · Cited by 109
Oakley, K. L., Moore, C. B., & Denning, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1124 · Cited by 100
Marco, F., Pfaller, M. A., Messer, S. A., & Jones, R. N. (1998) · Medical Mycology · doi:10.1080/02681219880000691 · Cited by 90
Self-citationEspinel-Ingroff, A., Bartlett, M., Chaturvedi, V., Ghannoum, M., Hazen, K. C., Pfaller, M. A., Rinaldi, M., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1828-1835.2001 · Cited by 83
Self-citationEmergence of Cryptococcal Disease: Epidemiologic Perspectives 100 Years after Its Discovery
Hajjeh, R. A., Brandt, M. E., & Pinner, R. W. (1995) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036195 · Cited by 81
Nomeir, A. A., Kumari, P., Hilbert, M. J., Gupta, S., Loebenberg, D., Cacciapuoti, A. F., Hare, R. S., Miller, G. H., Lin, C., & Cayen, M. N. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.727-731.2000 · Cited by 72
Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children
Tollemar, J. G., Klingspor, L., & Ringdén, O. T. H. (2001) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2001.tb00012.x · Cited by 71
Marco, F., Pfaller, M. A., Messer, S. A., & Jones, R. N. (1998) · Mycopathologia · doi:10.1023/a:1006970503053 · Cited by 54
Self-citationDiekema, D. J., Pfaller, M. A., Messer, S. A., Houston, A. K., Hollis, R. J., Doern, G. V., Jones, R. N., & The SENTRY PARTICIPANTS GROUP (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2236 · Cited by 40
Self-citationMarco, F., Pfaller, M. A., Messer, S. A., & Jones, R. N. (1998) · Medical Mycology · doi:10.1046/j.1365-280x.1998.00170.x · Cited by 28
Self-citationEditorial Response: The Epidemiology of Invasive Mycoses--Narrowing the Gap
Pfaller, M. A. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1148 · Cited by 26
Self-citation
Cited by
MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis
Singhal, N., Kumar, M., Kanaujia, P. K., & Virdi, J. S. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00791 · Cited by 1,605
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,345
Aspergillus flavus: human pathogen, allergen and mycotoxin producer
Hedayati, M. T., Pasqualotto, A. C., Warn, P. A., Bowyer, P., & Denning, D. W. (2007) · Microbiology · doi:10.1099/mic.0.2007/007641-0 · Cited by 964
Epidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
Metadata
- Authors
- Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2002-04
- Volume
- 46
- Issue
- 4
- Pages
- 1032-1037
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2127806652
- Cited by
- 404
- References
- 39
- FWCI
- 26.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.